Management of Bone Disease and Body Composition Changes

  • Author: Donald P. Kotler, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 5/7/18 (What's New)

Summary

  • In November 2010, the FDA approved tesamorelin to induce and maintain a reduction in excess visceral abdominal fat in HIV-infected patients with lipodystrophy
    • In a randomized, controlled trial, visceral fat content decreased by 15.4% in HIV-infected patients treated with tesamorelin for 26 weeks, compared with a 5.0% increase observed for those patients receiving placebo[Falutz 2010]
    • In a phase III confirmatory study, tesamorelin treatment in the context of ART resulted in sustained decreases in visceral adipose tissue for 52 weeks

Action required